IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)          Journal is Currently Not Indexed in Scopus as on february 2021 list provided by scopus

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Molecular Docking Studies Of Some Novel Furan Derivatives As Potent Inhibitors Of Staphylococcus Aureus

Author: JUDY JAYS, S MOHAN, J SARAVANAN
Abstract: With the emergence of multiple drug resistance strains of S.aureus, there is a deficiency in the treatment options available for the infections caused by these microorganisms. In attempts to develop lead antibacterial agents, especially targeting S.aureus, a series of novel furan-azetidinone hybrid compounds have been synthesized. Docking simulations were performed for the novel hybrid compounds at the active site of four antibacterial targets- Dihydrofolate reductase (PDB: 3SRW), DNA gyrase (-PDB: 5BS3), Dihydropteroate synthetase (PDB: 1AD4) and pyruvate kinase (PDB: 3T07). Molecular docking studies are capable of predicting the activity of an experimental set of compounds as they offer important information of the potential binding modes of inhibitors. This study explores the furan-azetidinone compounds as prospective inhibitors of four essential enzymes of S.aureus. The title compounds have shown good docking scores for dihydrofolate reductase enzyme of S.aureus. Molecular docking suggests that compound 4b (2-hydroxy derivative) is a prospective inhibitor of Dihyfrofolate reductase and is specific in binding at the active site of the enzyme. It forms H-bonding interaction with PHE 36 at the active site of the protein, similar to the standard drug. However the test compounds show lower docking scores against DNA gyrase, Dihydroteroate synthetase and pyruvate kinase of S.aureus signifying that they may not be effective against these bacterial proteins.
Keyword: Furan, Azetidinone, Docking, S.aureus
DOI: https://doi.org/10.31838/ijpr/2019.11.01.025
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free